Fact CheckerSign in

NCT04144972Recruiting

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S

Source: ClinicalTrials.gov · Last updated 31 Jul 2026

Brief summary (registry, in English)

Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24/7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
12 (estimated)
First submitted
28 Oct 2019
Start date
24 Oct 2019
Primary completion date
24 Oct 2029
Lead sponsor
University of California, San Francisco
Diseases
Stroke
NCT number
NCT04144972

What you commit to

  • Study type: Interventional
  • Planned participants: 12
  • From 24 Oct 2019 to the primary completion date, 24 Oct 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Pregnancy or breast feeding: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.
  • MR abnormalities that suggest an alternative diagnosis or contraindicate surgery
  • Previous cranial ablative surgery.
  • Previous deep brain stimulation surgery using an RC+S incompatible system
  • Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)

Other illness

  • Presence of cardiac pacemakers/defibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators not compatible with RC+S system
  • Active depression (BDI \> 20), Suicide attempt \</= 12 months or imminent suicide risk, or other untreated or uncontrolled psychiatric illness that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation.
  • History of substance abuse in past 3 years
  • Major neurological disorder other than the one that led to the chronic pain including epilepsy or a neurodegenerative condition including inability to recharge the device.
  • Allergies or known hypersensitivity to materials in the Summit RC+S system
  • Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.

Lab values

  • Inability to stop anticoagulation or platelet anti-aggregation therapy for surgery and recovery.

Age

  • Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant related infections, immunocompromised state or malignancy with \< 5 years life expectancy

Other

  • Implantable hardware not compatible with MRI or with the study.

Who the study is looking for

  • Age 22-80 years old
  • Clinical diagnosis of a refractory chronic pain syndrome including
    • post-traumatic pain syndromes (e.g. root avulsions, nerve crush injuries, spinal cord injury)
    • postsurgical pain syndromes (e.g., postmastectomy syndrome, post-thoracotomy syndrome, phantom limb pain, post-surgical spinal pain)
    • postherpetic neuralgia
    • complex regional pain syndrome
    • atypical facial pain
    • central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)
    • post-radiation plexopathy
  • Two or more years or more of medically refractory severe pain
  • Average daily pain for the past 30 days reported as \>6 on a 0-10 numeric rating scale (NRS)
  • Pain that fluctuates over a range of at least 3 points on the NRS
  • Patient has failed at least two pain medications from different classes as determined by a neurologist or pain management specialist with stable doses of medications for 30 days prior to baseline visit.
  • Lack of a surgically correctible etiology for the pain as determined by 2 independent surgeons
  • Ability to speak / read English
  • Capable of understanding and providing informed consent
  • Absence of significant cognitive impairment - score of 25 or greater on the Montreal Cognitive Assessment (MoCA)
  • Successful detection of pain biomarkers or positive symptomatic response to inpatient stimulation trial period if performed.

Age in the registry: 22 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of California San Francisco
Coordinator of this site? Confirm its status
San FranciscoUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.